Skip to content
Review Open access

HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial

Aug 2026 · Therapeutic Advances in Medical Oncology · Vol 18 · 0 citations · 32 references
Medicine

TL;DR

HLX07 monotherapy has demonstrated promising efficacy and a favorable safety profile in treating aCSCC, warranting further investigation in large-scale clinical studies.

Abstract

Background: Cutaneous squamous cell carcinoma (CSCC) accounts for 20% of all cutaneous cancers. Systemic treatment options for advanced CSCC (aCSCC) include immunotherapy, chemotherapy, and epidermal growth factor receptor (EGFR)-targeted therapy, although their efficacy is limited. HLX07 is a novel anti-EGFR antibody that showed preliminary anti-cancer activity and tolerability in phase I studies. Objectives: To evaluate the efficacy and safety of HLX07 in patients with aCSCC. Design: This is a multicenter, open-label, two-part phase II study. In Part 1, patients with metastatic or locally aCSCC not amenable to surgery or curative radiotherapy received 1500 mg (group A) or 1000 mg (group B) HLX07 intravenously every 3 weeks. In Part 2, patients received HLX07 at dose level determined with Part 1 results. Methods: The primary endpoint was objective response rate (ORR) assessed by an independent radiology review committee (IRRC). Secondary endpoints included other efficacy endpoints, safety, pharmacokinetics, immunogenicity, and quality of life. Results: Here we focus on Part 1 data. As of April 30, 2024, 31 patients were enrolled (group A, 21; group B, 10). Most patients had metastatic disease (85.7%; 90.0%). Per IRRC assessments, ORR was 19.0% (95% confidence interval (CI), 5.5–41.9) for group A and 60.0% (26.2–87.8) for group B; median progression-free survival was 4.9 (95% CI, 1.4–6.5) and 7.9 (95% CI, 2.2–11.1) months, and median duration of response was 5.0 (95% CI, 2.9–not evaluable (NE)) and 7.4 (95% CI, 2.8–NE) months, respectively. Median overall survival was 11.8 months (95% CI, 5.9–NE) and not reached (95% CI, 2.2–NE). Grade ⩾3 treatment-related adverse events (TRAEs) occurred in 8 (38.1%) and 3 (30.0%) patients, respectively. No TRAE leading to death or treatment discontinuation was reported. Conclusion: HLX07 monotherapy has demonstrated promising efficacy and a favorable safety profile in treating aCSCC, warranting further investigation in large-scale clinical studies. Trial registration: ClinicalTrials.gov NCT05238363.

Read PDF

Similar papers

Clinical trial Open access Sep 2026

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study

Abstract Background While immune checkpoint inhibitor-based neoadjuvant therapy shows promise in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the optimal regimen has yet to be established. We report, for the first time, a neoadjuvant treatment that combines chemotherapy with dual blockade of the p...

Zhi-Gong Wei, Hui-Jiao Chen, De-Juan Wang et al. · 0 citations
Open access Sep 2026

Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

BACKGROUND Bispecific antibody-drug conjugates (ADCs) may overcome limitations of monospecific ADCs. We report results from a phase 1b study of iza-bren, a first-in-class EGFR-HER3 bispecific ADC, in patients with heavily pretreated locally advanced or metastatic breast cancer. PATIENTS AND METHODS This multicenter s...

J. Zhang, Y. Meng, Y. Du et al. · 0 citations
Review Aug 2026

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.

Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al. · 0 citations
Open access Sep 2026

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.

Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment landscape of metastatic or...

Firas Hatoum, Brandon J. Dyer, Jazlyn Heiligh et al. · 0 citations
Open access Sep 2026

A multicenter retrospective study on the clinical features of patients with human epidermal growth factor receptor 2-positive colorectal cancer (HGCSG2304)

In metastatic colorectal cancer (mCRC), human epidermal growth factor receptor 2 (HER2)-positive disease is a molecular subtype for targeted therapy; however, real-world data remain limited. A multicenter retrospective study of patients with HER2-positive mCRC diagnosed between 2010 and 2023 at 14 institutions in Japan...

S. Kaneko, K. Sawada, K. Hatanaka et al. · 0 citations
Review Sep 2026

Immune Checkpoint Inhibition in Locally Advanced, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma.

Cutaneous squamous cell carcinoma (cSCC) is a potentially aggressive non-melanoma skin cancer with rising incidence attributed to ultraviolet radiation exposure, chronic inflammation, aging, immunosuppression, and improved detection technology. Immune checkpoint inhibitors (ICIs) have transformed treatment for advanced...

A. Vromans, Bridget Harrop, Nicole Flores et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.